ArticleERJ open research2024
The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583.
James D Chalmers et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
7 papers cite it
this papertrialcites it